IRulya Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
IRulya Therapeutics Inc IRLA
$37.82
▲ +11.98%
(+$4.05)
⬆️ Above Yest. High
🎈 Low Float
📅 Earnings This Week
Open
$34.13
Prev Close
$33.78
Day Range
$32.57 – $39.93
52W Range
$25.13 – $41.00
Market Cap
$34.35M
Beta
3.42
EPS (TTM)
$-125.71
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2019-05-09 |
| Shares Out. | 10,840,000 |
| Website | quincetx.com ↗ |
| Phone | 14159105717 |
| Employees | 38 |
About IRulya Therapeutics Inc
IRulya Therapeutics Inc is committed to transforming the lives of patients with serious, underserved diseases by developing disease-modifying therapies. The company is currently developing LAM-001 for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD), bronchiolitis obliterans syndrome post-lung transplant (BOS), and sarcoidosis-associated pulmonary hypertension (SAPH). A Phase 2a study in PH patients has been completed; a Phase 2 clinical study in BOS patients is ongoing; a Phase 2b clinical study in PH-ILD is ongoing; and a Phase 2 clinical study in SAPH is ongoing.
IRulya Therapeutics Inc is a publicly traded company under the ticker symbol IRLA on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
14 analysts (2026-11-01)